LIANTONIO, ANTONELLA
 Distribuzione geografica
Continente #
NA - Nord America 5.155
EU - Europa 1.046
AS - Asia 399
OC - Oceania 4
SA - Sud America 4
AF - Africa 3
Totale 6.611
Nazione #
US - Stati Uniti d'America 5.149
CN - Cina 331
SE - Svezia 283
IT - Italia 231
UA - Ucraina 155
DE - Germania 109
FI - Finlandia 103
GB - Regno Unito 72
FR - Francia 39
BE - Belgio 31
VN - Vietnam 27
IN - India 20
IE - Irlanda 10
IR - Iran 10
CA - Canada 6
NL - Olanda 5
CL - Cile 4
JP - Giappone 4
AU - Australia 3
HK - Hong Kong 3
CH - Svizzera 2
MA - Marocco 2
RU - Federazione Russa 2
BD - Bangladesh 1
DK - Danimarca 1
EE - Estonia 1
KE - Kenya 1
LT - Lituania 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
SG - Singapore 1
TR - Turchia 1
Totale 6.611
Città #
Fairfield 738
Woodbridge 566
Chandler 439
Houston 386
Jacksonville 377
Ashburn 351
Cambridge 316
Seattle 285
Nyköping 249
Wilmington 241
Ann Arbor 232
Lawrence 104
Roxbury 103
Bari 102
Nanjing 87
Princeton 82
Des Moines 67
New York 61
Inglewood 60
Beijing 50
Boardman 39
San Diego 36
Nanchang 32
Brussels 31
Jiaxing 30
Dong Ket 27
Hebei 27
Shenyang 27
Falls Church 20
Milan 19
Dearborn 16
London 15
Changsha 14
Los Angeles 14
Paris 13
Helsinki 12
Pune 12
San Mateo 12
Dublin 10
Tianjin 10
Zhengzhou 10
Genova 9
Hefei 9
Monmouth Junction 9
Redwood City 9
Taranto 9
Ardabil 8
Augusta 8
Brooklyn 7
Leawood 7
Kunming 6
Washington 6
Indiana 5
Jinan 5
Ningbo 5
Norwalk 5
Prescot 5
Toronto 5
Campobello Di Mazara 4
Genoa 4
Grafing 4
Marseille 4
San Francisco 4
Trani 4
Guangzhou 3
Kilburn 3
Santa Marinella 3
Sennori 3
Acton 2
Altamura 2
Bollate 2
Cisano Bergamasco 2
Fuzhou 2
Haikou 2
Hong Kong 2
Hounslow 2
Ksar el Kbir 2
Martina Franca 2
Mumbai 2
New Bedfont 2
Nulvi 2
Santiago 2
Tokyo 2
Torino 2
Trieste 2
Vinovo 2
Zurich 2
Apricena 1
Aradeo 1
Arzano 1
Auckland 1
Barletta 1
Brisbane 1
Castellammare Di Stabia 1
Chicago 1
Chions 1
Chiswick 1
Chongqing 1
Copenhagen 1
Detroit 1
Totale 5.526
Nome #
Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia 138
Effects of Nandrolone in the counteraction of skeletal muscle atrophy in a mouse model of muscle disuse: molecular biology and functional evaluation 135
ATP Sensitive Potassium Channels in the Skeletal Muscle Function: Involvement of the KCNJ11(Kir6.2) Gene in the Determination of Mechanical Warner Bratzer Shear Force 135
Ion channels in drug discovery and safety pharmacology 119
Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin 118
Antioxidant treatment of hindlimb-unloaded mouse counteracts fiber type transition but not atrophy of disused muscles 114
Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options 111
On the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles 109
Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy. 107
Activation and inhibition of kidney CLC-K chloride channels by fenamates 106
Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia 100
Structural requisites of 2-(p-chlorophenoxy)propionic acid analogues for activity on native rat skeletal muscle chloride conductance and on heterologously expressed CLC-1 98
Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system 98
Carboxylic acids and skeletal muscle chloride channel conductance: Effects on the biological activity induced by the introduction of an aryloxyalkyl group α to the carboxylic function of 4-chloro-phenoxyacetic acid 97
Recovery of the soleus muscle after short- and long-term disuse induced by hindlimb unloading: effects on the electrical properties and myosin heavy chain profile 95
Pharmacological characterization of chloride channels belonging to the ClC family by the use of chiral clofibric acid derivatives 92
null 92
Pre-clinical trials in Duchenne dystrophy: what animal models can tell us about potential drug effectiveness 91
Pharmacovigilance database search discloses ClC-K channels as a novel target of the AT1 receptor blockers valsartan and olmesartan 91
null 90
The alteration of calcium homeostasis in adult dystrophic mdx muscle fibers is worsened by a chronic exercise in vivo 88
Taurine and skeletal muscle ion channels 87
Change of chloride ion channel conductance is an early event of slow-to-fast fibre type transition during unloading-induced muscle disuse 87
Fiber type-related changes in rat skeletal muscle calcium homeostasis during aging and restoration by growth hormone 87
Alteration of excitation-contraction coupling mechanism in extensor digitorum longus muscle fibres of dystrophic mdx mouse and potential efficacy of taurine 87
null 86
Phosphorylation and IGF-1-mediated dephosphorylation pathways control the activity and the pharmacological properties of skeletal muscle chloride channels 82
Identification of sites responsible for the potentiating effect of niflumic acid on ClC-Ka kidney chloride channels 81
Niflumic acid inhibits chloride conductance of rat skeletal muscle by directly inhibiting the CLC-1 channel and by increasing intracellular calcium 81
Paracrine Effects of IGF-1 Overexpression on the Functional Decline Due to Skeletal Muscle Disuse: Molecular and Functional Evaluation in Hindlimb Unloaded MLC/mIgf-1 Transgenic Mice 80
Molecular determinants of differential pore blocking of kidney CLC-K chloride channels 77
Therapeutic approaches to genetic ion channelopathies and perspectives in drug discovery 74
A multidisciplinary evaluation of the effectiveness of cyclosporine A in dystrophic mdx mice 73
Involvement of Barttin Subunit in Pharmacological Potentiation of CLC-K Channels Expressed in Xenopus Oocytes 72
New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse 72
Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1 72
Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle 71
JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia 70
Paving the way for Bartter syndrome type 3 drug discovery: a hope from basic research 70
Taurine and skeletal muscle disorders 69
Pharmacology of CLC chloride channels and transporters 69
null 69
null 68
Peptidic and Nonpeptidic Growth Hormone Secretagogues exert a protective effect on mitochondrial parameters analysed in a rat model of cachexia 65
Kidney CLC-K chloride channels inhibitors: structure-based studies and efficacy in hypertension and associated CLC-K polymorphisms. 65
Effect of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle 64
Investigations of pharmacologic properties of the renal CLC-K1 chloride channel co-expressed with barttin by the use of 2-(p-Chlorophenoxy)propionic acid derivatives and other structurally unrelated chloride channels blockers 63
Potential targets for skeletal muscle impairment by hypogravity: basic characterization of resting ionic conductances and mechanical threshold of rat fast- and slow-twitch muscle fibers 63
Targeting kidney CLC-K channels: pharmacological profile in a human cell line versus Xenopus oocytes 63
Protein Kinase C-Theta Controls the CLC-1 Chloride Channel Function and Skeletal Muscle Phenotype: A Biophysical and Gene Expression Study in Pkc-Theta Null Mice 62
Statins and fenofibrate affect skeletal muscle chloride conductance in rats by different impairing ClC-1 channel regulation and expression 62
Molecular switch for CLC-K Cl– channel block/activation: Optimal pharmacophoric requirements towards high-affinity ligands 62
Investigating a Benzofurane Derivative Binding Site on Human CLC-5 61
I-J loop involvement in the pharmacological profile of CLC-K channels expressed in Xenopus oocytes 61
Therapeutic approaches to ion channel diseases 60
Growth hormone secretagogues exert differential effects on skeletal muscle calcium homeostasis in male rats depending on the peptidyl/non-peptidyl structure 59
Comparison of excitability parameters and sodium channel behavior of fast- and slow-twitch rat skeletal muscles for the study of the effects of hindlimb suspension, a model of hypogravity. 58
Disuse of rat muscle in vivo reduces protein kinase C activity controlling the sarcolemma chloride conductance 58
Effect of rat hindlimb suspension on cable properties, ionic conductances and fiber type composition of slow-twitch muscle. 58
Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies 56
Decrease in resting calcium and calcium entry associated with slow-to-fast transition in unloaded rat soleus muscle 55
null 55
Functional Study of Novel Bartter's Syndrome Mutations in ClC-Kb and Rescue by the Accessory Subunit Barttin Toward Personalized Medicine 55
Mechanism of Interaction of Niflumic Acid with Heterologously Expressed Kidney CLC-K Chloride Channels 53
Mechanism of block of single protopores of the Torpedo chloride channel ClC-0 by 2-(p-chlorophenoxy)butyric acid (CPB) 52
Potential benefits of taurine in the prevention of skeletal muscle impairment induced by disuse in the hindlimb-unloaded rat 51
Molecular determinants of 2(p-chlorophenoxy)propionic acid for modulation of the native chloride channel conductance of rat skeletal muscle 51
Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid 51
Calcium homeostasis is altered in skeletal muscle of spontaneously hypertensive rats cytofluorimetric and gene expression analysis 50
null 49
Block of renal CLC-K channels by phenoxy-alkyl derivatives of clofibric acid 48
Potent effect of chiral derivative of mexiletine on rat skeletal muscle sodium channel 47
Kv1.1 channelopathies: Pathophysiological mechanisms and therapeutic approaches 47
Antioxidant treatment of hindlimb-unloaded mouse in vivo counteracts fiber type transition but not atrophy of disused skeletal muscles 46
Age-dependent effects of disuse on electrophysiogical parameters and calcium homeostasis in the soleus muscle of hindlimb-unloaded mice 46
null 45
Potent and stereoselective use-dependent block of skeletal muscle Na+ channels by a new proline-like tocainide derivative 44
Farmaci per il trattamento delle malattie muscolari 41
Protein kinase C theta (PKCθ) modulates the ClC-1 chloride channel activity and skeletal muscle phenotype: a biophysical and gene expression study in mouse models lacking the PKCθ 40
Niflumic acid derivatives modulate macroscopic chloride conductance of native rat skeletal muscle by inhibiting the CLC-1 channel and by increasing the intracellular calcium level 39
Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach 39
Taurine ameliorates in vitro and in vivo the electrical and contractile properties of skeletal muscle fibres of dystrophic mdx mouse 38
Mechanisms of block of muscle type CLC chloride channels 38
In-vivo administration of CLC-K kidney chloride channels inhibitors increases water diuresis in rats: A new drug target for hypertension? 38
Alteration of stim1/orai1-mediated soce in skeletal muscle: Impact in genetic muscle diseases and beyond 37
Gain-of-Function STIM1 L96V Mutation Causes Myogenesis Alteration in Muscle Cells From a Patient Affected by Tubular Aggregate Myopathy 36
Pharmacology of chloride channels belonging to the CLC family 34
On the mechanism of the interaction of niflumic acid with kidney CLC-K chloride channels 34
Inflammatory pathways and dystrophic progression: effect of in vivo treatment with either target-specific or wide-acting drugs on functional, biochemical and histological markers of muscle damage in exercised mdx mice 33
Investigation of human CLC-K kidney channel block by extracellular ligands 33
Independent impairment of chloride channel function and calcium homeostasis in dystrophic muscle of exercised MDX mouse 32
Evaluation of drug efficacy on muscular dystrophy by in vivo treatments in exercised mdx mouse 28
Skeletal muscle impairment during microgravity-induced disuse: Beneficial effects of different pharmacological countermeasures 28
Growth hormone secretagogues modulate the electrical an contractile properties of rat skeletal muscle through a ghrelin-specific receptor 27
Increased sarcolemma chloride conductance as one of the mechanisms of action of carbonic anhydrase inhibitors in muscle excitability disorders 27
An olive oil-derived antioxidant mixture ameliorates the age-related decline of skeletal muscle function 26
Simulated microgravity modifies the activity of protein kinase C and serine-threonine phosphatase controlling the resting chloride channel conductance in skeletal muscle 25
Effetti sulla conduttanza dei canali al cloro della muscolatura scheletrica indotti dall’introduzione di un sostituente arilossialchilico in a alla funzione carbossilica dell’acido 4-cloro-fenossiacetico 23
Renal CLC-K chloride channels heterologously coexpressed with barttin are specifically affected by 2-(p-chlorophenoxy)propionic acid derivatives 23
Evaluation of biophysical and pharmacological properties of chloride channels belonging to ClC family by the use of chiral clofibric acid derivatives 22
Totale 6.534
Categoria #
all - tutte 27.998
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.998


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019449 0 0 0 0 0 0 0 0 0 0 223 226
2019/20201.717 298 95 43 157 177 111 197 147 218 83 144 47
2020/20211.196 140 61 80 99 107 35 92 65 113 193 133 78
2021/2022869 42 143 10 32 42 63 48 37 56 57 132 207
2022/20231.254 200 113 94 91 125 187 13 147 192 17 36 39
2023/2024445 31 79 26 65 50 106 24 20 5 36 3 0
Totale 6.891